Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-10-15

• Fields of study

  Medicine

• Identifiers
  PMID 11606388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Met-HGF/SF: tumorigenesis, invasion and metastasis.

  2007cited by this paper
• Growth factors and their receptors in cancer metastasis

  2002cited by this paper
• A white paper: the product of a pancreas cancer think tank.

  2001cited by this paper
• NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells

  2001influential reference
• HGF-c-Met Receptor Pathway in Tumor Invasion-metastasis and Potential Cancer Treatment With NK4

  2001cited by this paper
• Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice.

  2000cited by this paper
• Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.

  2000cited by this paper
• Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

  2000cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.

  2000cited by this paper
• Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4

  2000cited by this paper
• Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells

  2000cited by this paper
• Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.

  2000cited by this paper
• Orthotopic Models of Human Pancreatic Cancer

  1999cited by this paper
• Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer.

  1999cited by this paper
• Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis

  1998cited by this paper
• Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.

  1998cited by this paper
• Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor

  1998cited by this paper
• The molecular and cellular biology of pancreatic cancer.

  1998cited by this paper
• Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.

  1997cited by this paper
• c‐met Expression in Pancreatic Cancer and Effects of Hepatocyte Growth Factor on Pancreatic Cancer Cell Growth

  1997cited by this paper
• Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

  1997cited by this paper
• HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor

  1997cited by this paper
• Inhibitory Effects of the Antiangiogenic Agent TNP‐470 on Establishment and Growth of Hematogenous Metastasis of Human Pancreatic Carcinoma in SCID Beige Mice In Vivo

  1997cited by this paper
• Pancreatic carcinoma in perspective: A continuing challenge

  1996cited by this paper
• Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

  1996cited by this paper
• Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice.

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Hepatocyte growth factor is a potent mitogen for normal human pancreas cells in vitro.

  1995cited by this paper
• The national cancer data base report on pancreatic cancer

  1995cited by this paper
• Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

  1995cited by this paper
• Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer.

  1995cited by this paper
• Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer.

  1994cited by this paper
• Pancreatic carcinoma.

  1992cited by this paper
• Biology of pancreatic cancer.

  1991cited by this paper
• Molecular cloning and expression of human hepatocyte growth factor

  1989cited by this paper
• Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.

  1984cited by this paper

• Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis.

  2026cites this paper
• Sindbis Virus Platform Provides an Oncolytic-Virus-Mediated and Immunotherapeutic Strategy to Overcome the Challenging Microenvironment of Pancreatic Cancer

  2025influential citation
• Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies

  2023cites this paper
• Recent advances in targeted therapy for pancreatic adenocarcinoma

  2023cites this paper
• Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus

  2021cites this paper
• Bone morphogenetic proteins mediate crosstalk between cancer cells and the tumour microenvironment at primary tumours and metastases (Review).

  2020cites this paper
• Molecular mediators of peritoneal metastasis in pancreatic cancer

  2020cites this paper
• Targeting HGF/c-MET Axis in Pancreatic Cancer

  2020cites this paper
• Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.

  2020cites this paper
• Biology, pathophysiology, and epidemiology of pancreatic cancer

  2019cites this paper
• FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model.

  2017cites this paper
• MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection

  2017cites this paper
• Title Hepatocyte growth factor reduces susceptibility to an irreversible epidermalgrowth factor receptor inhibitor in EGFR-T 790 M mutant lung cancer

  2017cites this paper
• 6 Endocrine Delivery System of NK 4 , an HGF-Antagonist and Anti-Angiogenic Regulator , for Inhibitions of Tumor Growth , Invasion and Metastasis

  2017influential citation
• A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest.

  2017cites this paper
• Hepatocyte Growth Factor Signaling Pathway as a Potential Target in Ductal Adenocarcinoma of the Pancreas

  2017cites this paper
• Anti-Tumour Effects of High Affinity L-type Amino Acid Transporter1 Inhibitors on Human Pancreatic Adencarcinoma Cells

  2017cites this paper
• Hypoxia‐inducible factor‐targeting prodrug TOP3 combined with gemcitabine or TS‐1 improves pancreatic cancer survival in an orthotopic model

  2016cites this paper
• The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway

  2016cites this paper
• Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.

  2016cites this paper
• Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer

  2016cites this paper
• Inflammatory fibroblasts in cancer

  2016cites this paper
• High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

  2015cites this paper
• Inhibition of Pathologic Corneal Neovascularization by Topical Application of a Novel Peptide In Vivo

  2015cites this paper
• Regulation of Hepatocyte Growth Factor in Mice with Pneumonia by Peptidases and Trans-Alveolar Flux

  2015cites this paper
• Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice

  2015cites this paper
• Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge

  2015cites this paper
• Estimation of plasma concentrations of hepatocyte growth factor in acute leukemia in Upper Egypt

  2015cites this paper
• Nicotine Reduces Survival via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment

  2015cites this paper
• Gene therapy in pancreatic cancer.

  2014cites this paper
• The novel Aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination

  2014cites this paper
• Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling

  2014cites this paper
• Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches

  2014cites this paper
• Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.

  2014cites this paper
• Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor.

  2014cites this paper
• Mechanisms of Hepatocyte Growth Factor Activation in Cancer Tissues

  2014cites this paper
• Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.

  2013cites this paper
• Physiological Roles and Therapeutic Implications of Hepatocyte Growth Factor for Angiogenesis

  2013cites this paper
• Soluble c‐Met protein as a susceptible biomarker for gastric cancer risk: A nested case‐control study within the Korean Multicenter Cancer Cohort

  2013cites this paper
• HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and Therapeutics

  2013influential citation
• HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.

  2013cites this paper
• Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.

  2013cites this paper
• Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer

  2012cites this paper
• Current Knowledge on Pancreatic Cancer

  2012influential citation
• Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer

  2012cites this paper
• Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma

  2012cites this paper
• Targeting the Met pathway in lung cancer

  2012cites this paper
• Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621

  2012cites this paper
• Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease

  2011cites this paper
• NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells.

  2011cites this paper
• Endocrine Delivery System of NK4, an HGF-Antagonist and Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis

  2011influential citation
• NK 4 Gene Expression Enhances 5-Fluorouracil-induced Apoptosis of Murine Colon Cancer Cells

  2011cites this paper
• Development of c-MET pathway inhibitors

  2011cites this paper
• Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells

  2011cites this paper
• An update on molecular research of pancreatic adenocarcinoma.

  2011cites this paper
• Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma

  2010cites this paper
• 54 Emerging Therapeutic Targets for Pancreatic Cancer

  2010cites this paper
• Anti-cancer approach with NK4: Bivalent action and mechanisms.

  2010cites this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cites this paper
• ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

  2010cites this paper
• A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo

  2010cites this paper
• Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis

  2010cites this paper
• 2 Murine L 1210 and P 388 Leukemias

  2010cites this paper
• MET as a target for treatment of chest tumors.

  2009cites this paper
• Clinical development of MET targeted therapy for human cancer

  2009cites this paper
• Pancreatic Cancer: Pathological Factors and TNM Staging

  2009cites this paper
• DESIGN AND CHARACTERIZATION OF POLYSACCHARIDE-BASED NON-VIRAL CARRIERS AIMING AT GENE TRANSFECTION AND GENETIC ENGINEERING FOR CELL THERAPY

  2009cites this paper
• The MET axis as a therapeutic target.

  2009cites this paper
• Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

  2009cites this paper
• Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

  2009cites this paper
• Pancreatic cancer: molecular pathogenesis and new therapeutic targets

  2009cites this paper
• Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Experimental Therapeutics, Molecular Targets, and Chemical Biology

  2009cites this paper
• Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer

  2009cites this paper
• Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis.

  2009cites this paper
• Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met–dependent tumors in animal models

  2009cites this paper
• Angioinhibitory Action of NK4 Involves Impaired Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association*

  2009cites this paper
• Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor‐specific T lymphocyte activation

  2009influential citation
• Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models

  2009cites this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2009cites this paper
• The effects of NK4 on viral myocarditis mice.

  2009cites this paper
• The biological role of HGF-MET axis in tumor growth and development of metastasis.

  2008cites this paper
• A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging

  2008cites this paper
• Molecular Diagnosis of Pancreatic Cancer : Review Series

  2008cites this paper
• Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.

  2008cites this paper
• NK4 gene therapy targeting HGF-Met and angiogenesis.

  2008cites this paper
• Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4

  2008cites this paper
• Augmented anti-tumor therapy through natural targetability of macrophages genetically engineered by NK4 plasmid DNA

  2008cites this paper
• Targeting the c-MET signaling pathway for cancer therapy.

  2008cites this paper
• Design, synthesis, and biological evaluation of potent c-Met inhibitors.

  2008cites this paper
• Original article HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells

  2008cites this paper
• Targeting the c-MET signaling pathway for cancer therapy

  2008cites this paper
• Molecular aspects of carcinogenesis in pancreatic cancer.

  2008cites this paper
• Molecular Signaling Pathways in Pancreatic Cancer

  2008cites this paper
• c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations*

  2008cites this paper
• HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.

  2008cites this paper
• HGF/MET signaling in ovarian cancer.

  2008cites this paper
• Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.

  2007cites this paper
• Microfabricated airflow nozzle for microencapsulation of living cells into 150 micrometer microcapsules

  2007cites this paper